Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
This is what I posted on X earlier today in response to a tweet about todays update.
The bit about considering all options caught my eye. Pure speculation on my part but I have always had this feeling that one of the big boys would rather have XF-73 all to themselves than share with Dest. Could a part or all rights offer for XF-73 be the reason for delay.
I have brought the above to your attention as nick2412 has done an excellent post on ADVFN which goes into a lot more detail but is very similar to what my thoughts were after the update today. I suggest you read it.
Come on then danrh I am all ears, please explain all the risks you are on about and share the wealth of knowledge you have on pharmaceuticals. By the way I have been tipping destiny when it was in the 30p range so most who followed me will be very happy now at 81p. What a prat.
For those of you who have been reading my posts will know by now how highly I rate XF-73. I have stated many times that it will be a Blockbuster drug and that it will eventually be the standard of care for virtually every operation in the future and this was confirmed by the company when I asked them in the recent presentation.
Now our CEO is also very excited about XF-73 and I will list some quotes below from him in my recent email exchange with him.
'We are totally focused on securing the best possible deal for our key stakeholders and one that makes the most of the significant market opportunity for this incredible product'.
'The incredible opportunities for XF-73 nasal in terms of both saving lives once it is approved and delivering for shareholders is the main reason I was so excited to join Destiny, and it remains my absolute priority to deliver on both these opportunities'.
I am expecting an update on XF-73 this week and what a great end to the year it would be if they confirm that they have entered exclusivity with a Global Top Ten Pharma. That would mean that I could still be correct as I stated our partner will be either GSK or Pfizer. GLA
Noix that is correct, but what most people don't know is that the initial study was done in Q1 2023 by NIAID and then they decided to expand the work. You have to ask yourself, why would NIAID do that? My understanding is the results were very good and that is the reason for further work. I am expecting an excellent update on the NIAID trials.
I am pretty confident we will get an update on or before the 22nd December, that's only 10 trading days to go. Hopefully a similar share price reaction to what we had in December last year when the company provided an update on M3. The share price rose by about 50%.
I have bought in recently and would appreciate others thoughts on what I think Altn will be producing next year.
I have them producing 50K ounces of gold. If aisc are $1100 and say gold price at $2000, then they should be generating $45Million profit before tax. They should be able to pay the debt of pretty quick and then start paying dividends.
I had a long chat with IR yesterday and it's too long to post everything so will mention what I think were the important points.
Company are still on track to publish AD for South Sudan on or before 15th December. I asked if the company could extend the deadline if work streams not completed and stay suspended. Response was we have not sought advice on that. This was very interesting for me as I asked the same question in September and the answer was we have sought advice and been told we can extend deadline and stay suspended. So the questions arises why have they not sought advice this time.
I asked what the work streams are and was told it is gaining approval from various different departments and then Government approval. AK has been and is still in SS and that is what he has been doing.
Accugas debt refinance is still expected to complete before end of 2023 and will issue an Rns.
Re Chad, some major changes would have to take place for Save to start discussions with the Chad Government and preferred route is still via ICC.
No plans to issue a trading update before the end of 2023.
Not much happening in Niger, it is a wait and see situation for now.
As we all know Dest were in discussions with multiple global pharma and this has been confirmed by CT. I believe that the company are now in exclusive discussions with a global pharma and the upfront payment, milestones and royalties are being discussed. I am pretty convinced that we will get an update soon.
Pro this is chat board and I am free to post what I hear, nobody is asking you to believe it and even I take it with a pinch of salt as after all they are rumours. I suggest you stop behaving like the chat board police and stop making accusations.
I posted on here a few months ago that I had heard that both GSK and Pfizer had shown an interest. I cannot confirm this as they are rumours but my money is on GSK. Look at the evidence, GSK are into AMR in a big way and many of our directors used to work for GSK. I have always maintained XF-73 will be a blockbuster drug and all the evidence points to that, so why would GSK not be interested. Not long now before we get an update.
Dest in the right place at the right time. AMR a top health threat warns WHO, see link below.
https://www.forbes.com/sites/ariannajohnson/2023/11/22/what-to-know-about-antimicrobial-resistance-a-top-global-public-health-threat-who-warns/?sh=377812537bef
Hi Nick, in this case there would be no upfront payment from NIAID as they would not be signing a licensing deal. NIAID would pay for the trials at no cost to dest but dest would retain all the rights. That means that dest in the future could sign a licensing deal with any pharma and demand an upfront payment. A win win for dest.
The company have stated they will give an update on this in Q4 so any day now.
As mentioned a few days ago I have been looking into why the NIAID pre clinical trial for XF-73 dermal has been delayed. Firstly this trial is being carried out by NIAID of US and is testing XF-73 on wounds and burns with the US army in mind. Originally the company said it would provide an update in Q2 2023, then Q3 and now Q4. So why has it been delayed by 6 months or so, the answer I think is that the trial has been enlarged and extended from what was originally planned. Now the interesting part, why would NIAD do that? If the results of the original trial were not good then surely you would stop the trial and not waste any further money testing, however if the results were very good then it is reasonable to assume that the trial would be enlarged and this is what I believe has happened.
From the research I have done I am very confident that the results from this trial will be very good and this does tie in with the excellent results that were released by CMS our China partner on XF-73 dermal superficial skin infections.
What I am hoping for in this update is that not only are the results very good but NIAID have decided that they want to fund clinical trials for XF-73 in burns and wounds. If this happens then not only will it be a hugh endorsement of XF-73, it will put a rocket under the share price. Not long to find out as Rns could drop any day. GLA